Table 2.
Clinical variables associated with weight loss nadir (N=1369).
| Estimate | SE | p-value | |
|---|---|---|---|
| Intercept | 75.1 | 3.3 | |
| Baseline BMI | |||
| 35-39.9 | 40.8 | 3.2 | <.0001 |
| 40-49.9 | 22.4 | 2.3 | <.0001 |
| 50-59.9 | 8.7 | 2.2 | <.0001 |
| 60+ | Reference | ||
| Pre-operative weight loss | |||
| >0% gain | −10.3 | 1.9 | <.0001 |
| 0-5% loss | −6.5 | 1.9 | 0.0007 |
| 5-10% loss | −7.0 | 1.9 | 0.0002 |
| 10-19% loss | −6.1 | 1.6 | 0.0002 |
| 20%+ loss | Reference | ||
| Diabetes group | |||
| No diabetes | Reference | ||
| Diabetes with HbA1c<9 | −4.4 | 1.3 | 0.0009 |
| Diabetes with HbA1c>=9 | −8.4 | 2.6 | 0.0012 |
| Age | |||
| 18-39 | Reference | ||
| 40-49 | −3.7 | 1.5 | 0.0142 |
| 50-59 | −5.0 | 1.6 | 0.0018 |
| 60+ | −8.6 | 2.1 | <.0001 |
| Surgical access | |||
| Open surgery | −3.2 | 1.2 | 0.0082 |
| Laparoscopic surgery | Reference | ||
| Waist circumference | |||
| <45 | 6.5 | 3.0 | 0.0309 |
| 45-49 | 0.4 | 2.3 | 0.860 |
| 50-54 | −1.7 | 2.1 | 0.429 |
| 55-59 | −1.7 | 2.1 | 0.416 |
| 60+ | Reference | ||
| Use of bupropion | |||
| Active use of medication | 6.2 | 2.0 | 0.0015 |
| Iron deficiency | |||
| Low Transferrin saturation (<15% men, <12% women) | −4.6 | 2.1 | 0.0296 |
| Cholesterol HDL ratio | |||
| <4 | −3.9 | 1.5 | 0.0107 |
| 4-4.9 | −4.3 | 1.6 | 0.0092 |
| 5+ | Reference | ||
| Motivated to lose weight (WLRQ1) | |||
| Extremely motivated compared to previous attempts | 5.1 | 2.0 | 0.0109 |
| Hypertension | |||
| Active diagnosis | −2.8 | 1.2 | 0.0200 |
| Liver pathology and baseline BMI | |||
| No fibrosis | Reference | ||
| Any Fibrosis with baseline BMI<50 kg/m2 | −10.6 | 3.3 | 0.0015 |
| Any Fibrosis with baseline BMI 50+ kg/m2 | −1.6 | 3.6 | 0.651 |